Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.51    -0.19 (-7.04%)
Bid:
2.50
Ask:
2.69
Spread: 0.19 (7.60%)
Market Cap: £2.59m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Trading Update

29 Jan 2025 07:00

RNS Number : 0986V
Litigation Capital Management Ltd
29 January 2025
 

 

29 January 2025

 

Litigation Capital Management Limited

("LCM" or the "Company")

 

Trading Update for First Half of 2025 Financial Year

 

Litigation Capital Management Limited (AIM:LIT), an alternative asset manager specialising in dispute financing solutions internationally, provides the following trading update for the first half of the 2025 financial year, covering the six months ended 31 December 2024.

 

During the period, we achieved four case wins and incurred three case losses, resulting in an aggregate multiple of invested capital (MOIC) of 3.7x on realisations. 

Period

Realisations (A$m)

Invested Capital (A$m)

MOIC multiple

H1

52

14

3.7x

 

 

 

Note: Invested Capital includes LCM capital invested into the three case losses in the period.

 

These realisations include the successful international arbitration claim brought against the Republic of Poland as announced on 8 October 2024. On a fair value basis, these realisations are expected to contribute A$4m to Total Income in the period as these cases collectively were held at a fair value of approximately A$48m prior to conclusion. 

 

Fair value movements on ongoing cases are expected to contribute positively in the period to the value of A$1m. This is inclusive of a A$7m write-down of the fair value of the Queensland Electricity case following the trial loss announced on 4 December 2024. 

 

After accounting for operating expenses, finance costs, foreign exchange and tax in the first half we anticipate reporting a modest Loss After Tax of approximately A$8m (H1 FY24: Profit After Tax of A$7.3m).

 

Net debt as of 31 December stood at A$40.1m (FY24: A$8.9m) primarily reflecting increased investment into ongoing cases. As announced by the Company on 2 December 2024, LCM entered into a new US$75m credit facility to support future growth.

 

New Commitments

New commitments in the first half of FY25 were A$25m (H1 FY24: A$90m). While the period saw fewer quality opportunities meeting our rigorous investment criteria, this ebb and flow of opportunities is not unusual, and we remain confident in future capital deployment prospects. 

 

 

Patrick Moloney, CEO of LCM , commented: "While the first half of FY25 has been a period of mixed results, we are pleased with the strong realisations achieved and the ongoing progress of our portfolio. The high multiple on invested capital reflects the value we continue to generate from our disciplined approach to dispute financing. We remain confident in our ability to deploy capital effectively and to deliver attractive returns for our stakeholders as we move into the second half of the financial year."

 

 

 

 

 

 

 

 

Notes

 

The figures in this RNS are all on an LCM-only basis. 

 

Notice of Results

 

We expect to report our interim results on 18 March 2025.

 

 

Enquiries

Litigation Capital Management

c/o Tavistock PR 

Patrick Moloney, Chief Executive Officer

David Collins, Chief Financial Officer

 

 

 

 

Cavendish (Nomad and Joint Broker) 

Tel: 020 7220 0500

Jonny Franklin-Adams, Isaac Hooper and Rory Sale (Corporate Finance)

Tim Redfern, Jamie Anderson (Corporate Broking)

Canaccord (Joint Broker)

Tel: 020 7523 8000

Bobbie Hilliam

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is an alternative asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

 

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

 

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

Inside Information

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKLBLEFLZBBX
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.